Q-omics provides the consensus-scored MIR2116 profile across patient tissues and cancer cell-line models. MIR2116 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR2116 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MIR2116 RNA expression shows 11,077 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, LUSC, and UVM as cancer lineages where MIR2116 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2116 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2116 survival associations across molecular data types. MIR2116 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2116 RNA expression–survival associations across cancer types. High MIR2116 expression shows unfavorable associations in LUAD, LGG, LIHC and SKCM, but favorable associations in UCS and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR2116 RNA expression.
This table summarizes MIR2116 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2116. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2116 shows higher tumor expression in LUSC, BLCA, KIRP, HNSC and STAD. The LUSC box plot shows higher MIR2116 RNA expression in tumor versus normal tissue (log2 FC = +0.438, t-test p = .001).
This table shows molecular features associated with MIR2116 in patient tissues and cancer cell lines. In patient samples, MIR2116 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
